Keyword: Biomarin Pharmaceutical

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

BioMarin knows winning drug names. For the second time, one of its drugs won our #FierceMadness tournament—thanks in large part to BioMarin employees.

First rule of ballot stuffing? To avoid raising red flags, don't overdo it. And that’s exactly what 34,035 #FierceMadness votes for Brineura did.

​​​​​​​The final showdown is set: BioMarin’s Brineura will face off against AstraZeneca’s Imfinzi in the drug name championship for 2018.

We're down to four, folks. The #FierceMadness Final Four field is set after an Elite Eight that featured both blowouts and close calls.

Never underestimate the power of positivity, which triumphed in the latest round of voting in FiercePharma’s drug-naming shootout.

In what was a fast and furious two-day round of voting, the #FierceMadness drug name tournament field has narrowed to just 16.

There's a new medicine atop of pharma's global pricing charts, and it's Spark Therapeutics' Luxturna.

Halfway into 2017, the FDA has beaten last year's drug-approvals tally with a crop featuring controversy, sales firepower and one very high price.

Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.